Akash Kapadia, MD
Urology · Roswell, GANPI 1881012391
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $63,339 with a category attached, or 78.9%. Boston Scientific accounts for 84.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $50,589 and has fallen 95.3% since, to $2,363 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $212.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$54K
- Coloplast$5K
- Teleflex LLC$809
- Endo Pharmaceuticals Inc.$687
- Endo USA, Inc.$513
- Accord Healthcare, Inc.$422
- plus $2K from 34 others
Across 4 payments — averaging $4039.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$16K
What the payments were for
- Grants$50,00079%
- Travel & lodging$2,7934%
- Food & beverage$10,14316%
- Education$4041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 72 | $53,549 |
| Coloplast | 90 | $4,940 |
| Teleflex LLC | 12 | $809 |
| Endo Pharmaceuticals Inc. | 26 | $687 |
| Endo USA, Inc. | 12 | $513 |
| Accord Healthcare, Inc. | 2 | $422 |
| Dendreon Pharmaceuticals LLC | 7 | $186 |
| SRS Medical Systems, Inc. | 1 | $175 |
| Laborie Medical Technologies Corp. | 3 | $161 |
| Sumitomo Pharma America, Inc. | 7 | $159 |
| Astellas Pharma US Inc | 6 | $157 |
| Merck | 6 | $155 |
| Medtronic | 4 | $155 |
| Carl Zeiss Meditec USA, Inc. | 1 | $114 |
| Tempus AI, Inc | 4 | $109 |
| Bayer | 5 | $100 |
| KARL Storz Endoscopy-america | 1 | $100 |
| Pfizer | 5 | $84 |
| Novartis | 3 | $74 |
| Ferring Pharmaceuticals Inc. | 3 | $68 |
| Tolmar, Inc. | 3 | $63 |
| AstraZeneca | 3 | $63 |
| Antares Pharma, Inc. | 1 | $50 |
| Calyxo, Inc. | 2 | $44 |
| Olympus America Inc. | 3 | $44 |
| Angiodynamics, Inc. | 1 | $38 |
| Johnson & Johnson | 1 | $32 |
| Ambu Inc. | 1 | $31 |
| Verity Pharmaceuticals Inc. | 2 | $30 |
| Procept Biorobotics Corporation | 1 | $27 |
| Innovation Technologies Inc | 1 | $25 |
| Pharmaand GmbH | 1 | $25 |
| Urogen Pharma, Inc. | 1 | $24 |
| Dentsply IH AB | 1 | $23 |
| Stimlabs LLC | 1 | $22 |
| Photocure Inc | 1 | $21 |
| Valencia Technologies Corporation | 1 | $19 |
| AbbVie | 1 | $15 |
| Immunitybio, Inc. | 1 | $14 |
| Bioprotect Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$50,000
- TITAN$3,155
- AMS 700$672
- XIAFLEX$479
- CAMCEVI$422
- AMS 700 CXR RTE KIT$361
- UroLift$328
- Barrigel$276
- REZUM$225
- AMS$207
- UroCuff$175
- Optilume BPH Drug Coated Balloon Catheter$147
- LithoVue$131
- LUMERA$114
How this compares
$63,339 in reported general payments places this provider in the 95th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 15 | $11,602 |
| Testosterone | 17 | $3,420 |
| Testosterone Cypionate | 20 | $1,208 |
| Tamsulosin Hcl | 106 | $882 |
| Silodosin | 18 | $786 |
| Finasteride | 25 | $389 |
| Cefdinir | 26 | $253 |
| Oxycodone Hcl | 41 | $85 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 34 | $82 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $65 |
| Sildenafil Citrate | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $157 | $11,60215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 369 urology providers in Georgia.
Other urology in Roswell
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Scott MillerRoswell$85K
- Sophia GoodridgeRoswell$18K
- Daniel BelewRoswell$16K
- Rutveej PatelRoswell$15K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.